Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

21Non-GAAP net loss$

(4,946)$

(4,185)(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance

(2) All share-based compensation was excluded for the non-GAAP Analysis.

(3) Due to the below market interest rate of the related party loan, total GAAP interest expense includes non-cash interest expense of $299 for the three months ended June 30, 2009.

(4) Represents a one-time French withholding tax on the $11,000 upfront payment from Servier.Pharmacyclics, Inc.
(a development stage enterprise)
Reconciliation of selected GAAP measures to non-GAAP measures (1)
(unaudited) (in thousands)Year EndedJune 30,20102009GAAP net loss$

(15,024)$

(23,447)Adjustments:   Celera Corporation Payment (2)-1,000   Research & Development stock-based compensation (3)

1,998738   General & Administrative stock-based compensation (3)

1,1922,555   Interest Adjustment for related party loan (4)21549   Withholding Tax (5)(550)5502,6615,392   License and collaboration revenues (6)(1,211)-(1,211)-Non-GAAP net loss$

(13,574)$

(18,055)(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance

(2) Includes a one time payment of $1,000 to Celera Corporation as part of the Servier License Agreement.

(3) All share-based compensation was excluded for the non-GAAP Analysis.

(4) Due to the below market interest rate of the related party loan, total GAAP interest expense includes non-cash interest expense of $21 and $549 for the twelve months ended June 30, 2010 and
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... TARRYTOWN, N.Y. , May 23, 2013 /PRNewswire/ ... reconstruction following mastectomy is an appropriate option ... mutations seeking to surgically reduce their breast cancer ... involves a gradual expansion process and a second ... of implants in the same surgery as mastectomy ...
(Date:5/23/2013)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very ... panel meeting for non-thermal shortwave diathermy: The ... Meeting was held on May 21, 2013 in ... the meeting was very narrow, in that the FDA ... application of non-thermal shortwave diathermy for the treatment of ...
(Date:5/23/2013)... , May 23, 2013  Datameer announced today ... enable data discovery on their big data platform. ... tools they need to quickly and easily visualize ... A Fortune 19 company, Cardinal Health is ... It provides pharmaceuticals and medical products to more ...
Breaking Medicine Technology:Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Cardinal Health Selects Datameer for Healthcare Data Discovery 2
... , , , ... AMGN ) today announced positive top-line results from a pivotal ... acid) administered as an intravenous (IV) infusion in the treatment of ... including breast and prostate cancer) or multiple myeloma. , ...
... , , , , ... Institute (KLRI) has published two new publications on hormone therapies and ... adults. , , Cardiovascular disease caused by atherosclerosis, ... greatest single killer of American women--40% of total deaths--and the rate ...
Cached Medicine Technology:Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 2Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 3Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 4Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 5Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 6Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 7Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 8TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 2TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 3
(Date:5/24/2013)... number of U.S. patients admitted to hospitals, intensive ... room has increased by nearly 50 percent, according ... researchers at the George Washington University School of ... found that patients wait five hours in the ... the ICU. The researchers said improved coordination between ...
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... discovery at Oregon Health & Science University highlights an ... infected with the highly evasive HIV virus that causes ... this unique approach to develop its own HIV vaccine ... animal studies. This latest research finding will be published ... Science . , "A major challenge in ...
(Date:5/24/2013)... 2013 CBT News.com recently announced the addition ... web-based retail automotive industry news organization with 12 years experience ... to join a group that’s so forward-thinking in their approach,” ... online video content is on the rise.” , Atlanta born ... and segued into advertising at Cycle News and Boating World. ...
(Date:5/24/2013)... 2013 American International College of ... an articulation agreement with Old Dominion University (ODU) ... in Antigua. , The program will permit ... in a cell biology course, taught by AICASA’s faculty, ... American University of Antigua (AUA) College of Medicine , ...
Breaking Medicine News(10 mins):Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2
... 1 Oral Session and 21 Poster Sessions ... Debuts New Clostridium difficile Program , LOUISVILLE, Colo., ... today that it will be presenting 21 posters,highlighting three ... Antimicrobial Agents and Chemotherapy (ICAAC) held at the,McCormick Place ...
... Centers to Offer Free Health Assessments, HARRISBURG, Pa., ... invited Pennsylvanians to take advantage of,free health assessments being ... Sept. 21. The free health services are available in,conjunction ... which is observed on,Sept. 18., "Nearly 800,000 Pennsylvanians ...
... to Lead Financing Strategies to Fund Growth, ... Bulletin Board: APHY) today announced that it has ... EFH ) to develop and,lead financing strategies. Assured ... for patients with chronic pain and other,long-term care ...
... strengthen brand recognition, national ... BUFFALO, N.Y., Sept. 17 Meritain Health, ... today announced,the name change of recently acquired benefits ... of Meritain Health. Meritain Health acquired Weyco ...
... 17 LifeNet Health, a leading,biomedical and allograft ... Wound Allograft Institute" in affiliation with The Living ... and most progressive,organ and tissue recovery organizations in ... Institute" will directly serve the needs of burn,patients ...
... asthma type, study concludes, , , MONDAY, Sept. 17 ... the type of asthma you develop, new research ... in affluent, developed countries had more allergy-triggered asthma ... countries. , "The link between atopic sensitization ...
Cached Medicine News:Health News:Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Health News:Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Health News:Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4Health News:Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 5Health News:Assured Pharmacy Retains Empire Financial Group 2Health News:Assured Pharmacy Retains Empire Financial Group 3Health News:Meritain Health Announces Name Change for Acquired Companies 2Health News:LifeNet Health Establishes 'The Skin & Wound Allograft Institute' 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3
Straight shafts with fine pierse type tips. Flat open serrated handle with dull finish....
Straight shafts with micro Pierse type tips. Flat open serrated handle, dull finish....
Micro pierse type tips with 2 mm angled Colibri style jaws. Flat open serrated handle, dull finish....
5 mm jaws with teeth provide secure fixation of occular structures....
Medicine Products: